REG1A and Hyperbilirubinemia: Determining optimal dosage regimens of both drugs for patients with advanced gastrointestinal cancer may reduce the risk of adverse reactions dependent on the concentration of REG (e.g., hyperbilirubinemia and liver function disorders) and its metabolites (e.g., hypertension and toxic erythema) in the blood.